- Home
- VBF vs AMRN Comparison
VBF vs AMRN Comparison
Compare VBF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.15
Company Overview
Basic Information| Metric | VBF | AMRN |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 287.9M |
| IPO Year | 1995 | 1998 |
Fundamental Metrics
Financial Performance| Metric | VBF | AMRN |
|---|---|---|
| Price | $14.26 | $13.15 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 83.9K | 46.5K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $14.18 | $12.96 |
| 52 Week High | $15.86 | $20.90 |
Technical Indicators
Market Signals| Indicator | VBF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 27.03 | 35.99 |
| Support Level | N/A | N/A |
| Resistance Level | $15.21 | $14.50 |
| Average True Range (ATR) | 0.17 | 0.39 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 19.60 | 12.90 |
Price Performance
Historical Comparison VBF
AMRN
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.